Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Infliximab/adverse effects"'
Autor:
Rachel W. Winter, Sonia Friedman, Jan Nielsen, Jens Kjeldsen, Bente Mertz Nørgård, Michael Due Larsen
Publikováno v:
Winter, R W, Friedman, S, Nielsen, J, Kjeldsen, J, Nørgård, B M & Larsen, M D 2022, ' Infliximab Is Not Associated With a General Long-Term Weight Gain in Patients With Inflammatory Bowel Disease : A Nationwide Study ', The American Journal of Gastroenterology, vol. 117, no. 5, pp. 777-784 . https://doi.org/10.14309/ajg.0000000000001721
INTRODUCTION: Patients with Crohn's disease (CD) and ulcerative colitis (UC) may lose weight during periods of active disease and may gain weight when inflammation heals. Studies have hypothesized an association between antitumor necrosis factor-alph
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10c739a1fd946f05fb0273e3f51acce2
https://doi.org/10.14309/ajg.0000000000001721
https://doi.org/10.14309/ajg.0000000000001721
Autor:
Alexander A. Navarini, Curdin Conrad, Alessio Mylonas, Anne-Karine Lapointe, Jeremy Di Domizio, Olivier Demaria, Michel Gilliet, Cyrine Belkhodja, Lars E. French, Maxime Vernez
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-11 (2018)
Nature Communications
Nature communications, vol. 9, no. 1, pp. 25
Nature Communications
Nature communications, vol. 9, no. 1, pp. 25
Although anti-tumor necrosis factor (TNF) agents are highly effective in the treatment of psoriasis, 2–5% of treated patients develop psoriasis-like skin lesions called paradoxical psoriasis. The pathogenesis of this side effect and its distinction
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbbc7decb248c10970a313c075620f0f
https://doaj.org/article/180fc992d72e4fcbbf1d606055e86015
https://doaj.org/article/180fc992d72e4fcbbf1d606055e86015
Autor:
Patricia Zacharias, Álvaro Steckert Filho, Diogo Araujo Ribeiro, Larissa Boaron, Mariella Bau, Paulo Gustavo Kotze
Publikováno v:
Arquivos de Gastroenterologia, Iss 0 (2017)
Arquivos de Gastroenterologia v.54 n.4 2017
Arquivos de gastroenterologia
Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia
instacron:IBEPEGE
Arquivos de Gastroenterologia, Volume: 54, Issue: 4, Pages: 328-332, Published: 21 SEP 2017
Arquivos de Gastroenterologia v.54 n.4 2017
Arquivos de gastroenterologia
Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia
instacron:IBEPEGE
Arquivos de Gastroenterologia, Volume: 54, Issue: 4, Pages: 328-332, Published: 21 SEP 2017
BACKGROUND: Infliximab and adalimumab are considered effective drugs in the management of Crohn’s disease. However, due to significant immunossupression, they can cause important adverse events, mostly infections. OBJECTIVE: The aim of this study w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d493b8feeef4f7d9b4bbcb6d45f61a1
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-28032017005009105&lng=en&tlng=en
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-28032017005009105&lng=en&tlng=en